180 related articles for article (PubMed ID: 21199886)
1. Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods.
Oakman C; Tenori L; Claudino WM; Cappadona S; Nepi S; Battaglia A; Bernini P; Zafarana E; Saccenti E; Fornier M; Morris PG; Biganzoli L; Luchinat C; Bertini I; Di Leo A
Ann Oncol; 2011 Jun; 22(6):1295-1301. PubMed ID: 21199886
[TBL] [Abstract][Full Text] [Related]
2. Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population.
Hart CD; Vignoli A; Tenori L; Uy GL; Van To T; Adebamowo C; Hossain SM; Biganzoli L; Risi E; Love RR; Luchinat C; Di Leo A
Clin Cancer Res; 2017 Mar; 23(6):1422-1431. PubMed ID: 28082280
[No Abstract] [Full Text] [Related]
3. Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study.
Tenori L; Oakman C; Morris PG; Gralka E; Turner N; Cappadona S; Fornier M; Hudis C; Norton L; Luchinat C; Di Leo A
Mol Oncol; 2015 Jan; 9(1):128-39. PubMed ID: 25151299
[TBL] [Abstract][Full Text] [Related]
4. A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer.
Jobard E; Pontoizeau C; Blaise BJ; Bachelot T; Elena-Herrmann B; Trédan O
Cancer Lett; 2014 Feb; 343(1):33-41. PubMed ID: 24041867
[TBL] [Abstract][Full Text] [Related]
5. Serum nuclear magnetic resonance-based metabolomics and outcome in diffuse large B-cell lymphoma patients - a pilot study.
Stenson M; Pedersen A; Hasselblom S; Nilsson-Ehle H; Karlsson BG; Pinto R; Andersson PO
Leuk Lymphoma; 2016 Aug; 57(8):1814-22. PubMed ID: 26887805
[TBL] [Abstract][Full Text] [Related]
6. Metabolomic prediction of endometrial cancer.
Bahado-Singh RO; Lugade A; Field J; Al-Wahab Z; Han B; Mandal R; Bjorndahl TC; Turkoglu O; Graham SF; Wishart D; Odunsi K
Metabolomics; 2017 Dec; 14(1):6. PubMed ID: 30830361
[TBL] [Abstract][Full Text] [Related]
7. NMR-based metabolomics identifies patients at high risk of death within two years after acute myocardial infarction in the AMI-Florence II cohort.
Vignoli A; Tenori L; Giusti B; Takis PG; Valente S; Carrabba N; Balzi D; Barchielli A; Marchionni N; Gensini GF; Marcucci R; Luchinat C; Gori AM
BMC Med; 2019 Jan; 17(1):3. PubMed ID: 30616610
[TBL] [Abstract][Full Text] [Related]
8. Early detection of recurrent breast cancer using metabolite profiling.
Asiago VM; Alvarado LZ; Shanaiah N; Gowda GA; Owusu-Sarfo K; Ballas RA; Raftery D
Cancer Res; 2010 Nov; 70(21):8309-18. PubMed ID: 20959483
[TBL] [Abstract][Full Text] [Related]
9. A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting.
Di Donato S; Vignoli A; Biagioni C; Malorni L; Mori E; Tenori L; Calamai V; Parnofiello A; Di Pierro G; Migliaccio I; Cantafio S; Baraghini M; Mottino G; Becheri D; Del Monte F; Miceli E; McCartney A; Di Leo A; Luchinat C; Biganzoli L
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199435
[TBL] [Abstract][Full Text] [Related]
10. The decrease of some serum free amino acids can predict breast cancer diagnosis and progression.
Eniu DT; Romanciuc F; Moraru C; Goidescu I; Eniu D; Staicu A; Rachieriu C; Buiga R; Socaciu C
Scand J Clin Lab Invest; 2019; 79(1-2):17-24. PubMed ID: 30880483
[TBL] [Abstract][Full Text] [Related]
11. Metabolomic studies of breast cancer in murine models: A review.
Araújo R; Bispo D; Helguero LA; Gil AM
Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165713. PubMed ID: 32014550
[TBL] [Abstract][Full Text] [Related]
12. Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum.
Zhang X; Xu L; Shen J; Cao B; Cheng T; Zhao T; Liu X; Zhang H
Biochim Biophys Acta; 2013 Aug; 1832(8):1207-16. PubMed ID: 23524237
[TBL] [Abstract][Full Text] [Related]
13. A Pilot Study on the Utility of Serum Metabolomics in Neuroblastoma Patients and Xenograft Models.
Beaudry P; Campbell M; Dang NH; Wen J; Blote K; Weljie AM
Pediatr Blood Cancer; 2016 Feb; 63(2):214-20. PubMed ID: 26481088
[TBL] [Abstract][Full Text] [Related]
14. A plasma metabolomic signature discloses human breast cancer.
Jové M; Collado R; Quiles JL; Ramírez-Tortosa MC; Sol J; Ruiz-Sanjuan M; Fernandez M; de la Torre Cabrera C; Ramírez-Tortosa C; Granados-Principal S; Sánchez-Rovira P; Pamplona R
Oncotarget; 2017 Mar; 8(12):19522-19533. PubMed ID: 28076849
[TBL] [Abstract][Full Text] [Related]
15. Predicting ovarian cancer recurrence by plasma metabolic profiles before and after surgery.
Zhang F; Zhang Y; Ke C; Li A; Wang W; Yang K; Liu H; Xie H; Deng K; Zhao W; Yang C; Lou G; Hou Y; Li K
Metabolomics; 2018 Apr; 14(5):65. PubMed ID: 30830339
[TBL] [Abstract][Full Text] [Related]
16. Metabolic fingerprinting in breast cancer stages through
Suman S; Sharma RK; Kumar V; Sinha N; Shukla Y
J Pharm Biomed Anal; 2018 Oct; 160():38-45. PubMed ID: 30059813
[TBL] [Abstract][Full Text] [Related]
17. Metabolomic profiling reveals potential biomarkers in esophageal cancer progression using liquid chromatography-mass spectrometry platform.
Zhang H; Wang L; Hou Z; Ma H; Mamtimin B; Hasim A; Sheyhidin I
Biochem Biophys Res Commun; 2017 Sep; 491(1):119-125. PubMed ID: 28711496
[TBL] [Abstract][Full Text] [Related]
18. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
19. [Evidence-based radiotherapy in the treatment of early-stage invasive breast cancer: traditional clinical features and biomarkers].
Fodor J
Magy Onkol; 2009 Mar; 53(1):7-14. PubMed ID: 19318321
[TBL] [Abstract][Full Text] [Related]
20. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
